

Appl. No. : 09/802,397
Filed : March 9, 2001

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method for producing an anti-tumor response in a mammalian subject, said method comprising administering to said subject a plurality of dendritic cell/tumor cell hybrids, wherein said dendritic cell is not a T-lymphocyte, B-lymphocyte, monocyte/macrophage or another non-dendritic cell present in enriched or purified dendritic cell preparations.

2. Canceled.

3. (Currently amended) A method for producing an anti-tumor response in a mammalian subject, said method comprising administering to said subject a dendritic cell/tumor cell hybridoma, wherein said dendritic cell is not a T-lymphocyte, B-lymphocyte, monocyte/macrophage or another non-dendritic cell present in enriched or purified dendritic cell preparations.

4. Canceled.

5. (Previously presented) The method of Claim 1 wherein the plurality of hybrids is further induced to express the dendritic cell characteristics before using said hybrids for the production of an anti-tumor response.

6. (Previously presented) The method of Claim 3 wherein the obtained hybridoma is further induced to express the dendritic cell characteristics before using said hybridoma for the production of an anti-tumor response.

7. (Previously presented) The method of Claim 5 wherein said dendritic cell characteristics are chosen from the group consisting of dendritic cell morphology, dendritic cell surface markers or dendritic cell activation markers and immune cell activation properties *in vitro*.

8. (Previously presented) The method of Claim 6 wherein said dendritic cell characteristics are chosen from the group consisting of dendritic cell morphology, dendritic cell surface markers or dendritic cell activation markers and immune cell activation properties *in vitro*.

9. (Previously presented) The method of Claim 5 wherein said induction is performed using GM-CSF.

Appl. No. : **09/802,397**
Filed : **March 9, 2001**

10. (Previously presented) The method of Claim 6 wherein said induction is performed using GM-CSF.

11. (Previously presented) The method of Claim 1 wherein the plurality of hybrids is treated to prevent proliferation before using said hybrids for the production of an anti-tumor response.

12. (Previously presented) The method of Claim 3 wherein the hybridoma is treated to prevent proliferation before using said hybridoma for the production of an anti-tumor response.

13. (Previously presented) The method of Claim 11 wherein said treatment occurs by irradiation.

14. (Previously presented) The method of Claim 12 wherein said treatment occurs by irradiation.

15. (Previously presented) The method of Claim 1 wherein said plurality of hybrids is administered by injection.

16. (Previously presented) The method of Claim 3 wherein said hybridoma is administered by injection.

17. (Previously presented) The method of Claim 15 wherein said injection is carried out parenterally.

18. (Previously presented) The method of Claim 16 wherein said injection is carried out parenterally.

19. (Currently amended) The method of Claim 1 wherein said dendritic cell is ~~derived~~purified from bone marrow.

20. (Currently amended) The method of Claim 3 wherein said dendritic cell is ~~derived~~purified from bone marrow.

21. (Previously presented) The method of Claim 1 wherein said dendritic cell is of myeloid origin.

22. (Previously presented) The method of Claim 3 wherein said dendritic cell is of myeloid origin.

23. (Previously presented) The method of Claim 1 wherein said dendritic cell is of lymphoid origin.

Appl. No. : **09/802,397**
Filed : **March 9, 2001**

24. (Previously presented) The method of Claim 3 wherein said dendritic cell is of lymphoid origin.

25-28. (Cancelled)

29. (New) The method of Claim 1 wherein the dendritic cell and/or the tumor cell is human in origin.

30. (New) The method of Claim 3 wherein the dendritic cell and/or the tumor cell is human in origin.

31. (New) The method of Claim 1 wherein the dendritic cell is a proliferating dendritic cell or a dendritic cell at a more immature stage.

32. (New) The method of claim 31, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is human in origin.

33. (New) The method of claim 31, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is purified from bone marrow.

34. (New) The method of claim 31, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is purified from blood.

35. (New) The method of claim 31, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is purified from lymph or lymph nodes.

36. (New) The method of claim 31, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is of myeloid origin.

37. (New) The method of claim 31, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is of lymphoid origin.

Appl. No. : **09/802,397**
Filed : **March 9, 2001**

38. (New) The method of claim 31, wherein said proliferation is induced by culturing DC precursors in the presence of cytokines.

39. (New) The method of claim 3, wherein said dendritic cell is a proliferating dendritic cell or a dendritic cell at a more immature stage.

40. (New) The method of claim 39, wherein said proliferating dendritic cell or said dendritic cell at a more immature stage is human in origin.

41. (New) The method of claim 39, wherein said proliferating dendritic cell or said dendritic cell at a more immature stage is purified from bone marrow.

42. (New) The method of claim 39, wherein said proliferating dendritic cell or said dendritic cell at a more immature stage is purified from blood.

43. (New) The method of claim 39, wherein said proliferating dendritic cell or the dendritic cell at a more immature stage is purified from lymph/lymph nodes.

44. (New) The method of claim 39, wherein said proliferating dendritic cell or said dendritic cell at a more immature stage is of myeloid origin.

45. (New) The method of claim 39, wherein said proliferating dendritic cell or said dendritic cell at a more immature stage is of lymphoid origin.

46. (New) The method of claim 39, wherein said proliferation is induced by culturing DC precursors in the presence of cytokines.

47. (New) The method of Claim 1, wherein said dendritic cell is purified from blood.

Appl. No. : **09/802,397**
Filed : **March 9, 2001**

48. (New) The method of Claim 1, wherein said dendritic cell is purified from lymph or lymph nodes.

49. (New) The method of Claim 3, wherein said dendritic cell is purified from blood.

50. (New) The method of Claim 3, wherein said dendritic cell is purified from lymph or lymph nodes.